Business Insights and Analytics

Our Insight team applies rigorous analysis and expert interpretation in order to provide strategic recommendations

Read more

Strategic and Scientific Consulting

Our Consulting team help solve complex scientific and commercial challenges throughout the product lifecycle

Read more

Scientific and Creative Communications

Our Communications team care passionately about the science and making evidence matter across the entire healthcare spectrum

Read more

Business Insights and Analytics

Plus icon

Our Insight team applies rigorous analysis and expert interpretation in order to provide strategic recommendations

Read more

Strategic and Scientific Consulting

Plus icon

Our Consulting team help solve complex scientific and commercial challenges throughout the product lifecycle

Read more

Scientific and Creative Communications

Plus icon

Our Communications team care passionately about the science and making evidence matter across the entire healthcare spectrum

Read more

Why we do what we do

The healthcare industry is going through fundamental change and in this uncertainty our clients need to convert great science into winning strategy

Our clients tell us they need our support in making the right strategic decisions that ensure their products fulfil their potential and ultimately improve people’s lives

We love working at the cutting edge, helping to tackle our clients’ newest and most complex problems

Teams of experts

We are expert navigators helping guide our clients to more successful outcomes

Our people

With a global perspective

We work with 24 of the top 25 pharmaceutical companies as well as 100s of biotechs globally from our offices in the US and Europe

Contact us

Solving unique problems

Whether we are supporting you on your journey, or delivering specialist expertise, we are helping you make important choices

How we work

Share our fresh thinking >

Harnessing Collective Social Identity in COVID-19
Harnessing Collective Social Identity in COVID-19
Countries around the world have had to impose strict restrictions on people’s normal daily lives and impose emergency measures to contain coronavirus.
BioPharma Deal-Making in the Time of Social Distancing
BioPharma Deal-Making in the Time of Social Distancing
Mutual trust is required to ink long-term collaborative deals, and that trust is best built over time and through recurrent face-to-face personal interactions.
Behavioural science and the Covid-19 pandemic
Behavioural science and the Covid-19 pandemic
On Thursday 12th March 2020, the prime minister of the UK gave a speech outlining the strategy for delaying the Covid-19 pandemic[1].
Is Novartis’ RNA Therapeutic Inclisiran Poised to Displace PCSK9 Antibodies and Become the Next Blockbuster Lipid-Lowering Drug?
Is Novartis’ RNA Therapeutic Inclisiran Poised to Displace PCSK9 Antibodies and Become the Next Blockbuster Lipid-Lowering Drug?
In the last several years, RNA-targeted platforms yielded FDA/EMA approved therapies for ultra-rare metabolic and neurodegenerative diseases that address significant unmet medical needs justifying high therapeutic value ($400 to >$800k annual cost of therapy).

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us